You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Bulk Pharmaceutical API Sources for FOSCARNET SODIUM


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for FOSCARNET SODIUM

Vendor Vendor Homepage Vendor Sku API Url
NovoSeek ⤷  Start Trial 44561 ⤷  Start Trial
NovoSeek ⤷  Start Trial 4488958 ⤷  Start Trial
Hangzhou APIChem Technology ⤷  Start Trial AC-2085 ⤷  Start Trial
ABI Chem ⤷  Start Trial AC1L2C37 ⤷  Start Trial
AKos Consulting & Solutions ⤷  Start Trial AKOS003599741 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk API Sources for Foscarnet Sodium

Last updated: February 20, 2026

Foscarnet sodium, a pyrophosphate analogue, is used primarily in antiviral therapy, notably for cytomegalovirus (CMV) and herpesvirus infections. Reliable sourcing of bulk API (Active Pharmaceutical Ingredient) for manufacturing is critical for quality control, regulatory compliance, and supply chain continuity.

Main Global Suppliers and Production Countries

Major API manufacturers distribute foscarnet sodium in a regulated global market. Key countries include China, India, and the United States, which host the majority of API-producing facilities.

Country Notable Manufacturers Market Share (Estimated) Notes
China Zhejiang Jiuzhou Pharmaceutical, Xi'an Guohua Pharmaceutical, Hainan Pharma 60% Largest producer, often supplies generics globally
India Cipla, Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries 20% Focus on generic manufacturing, regulated exports
United States Teva Pharmaceuticals, Pfizer (limited API manufacturing) 10% API procurement mainly through imports
Others South Korea, Europe (small-scale producers) 10% Focused on niche markets or R&D batches

Regulatory Status and Quality Standards

Sources must comply with regulatory approvals, including the US FDA, EMA, and local authorities.

  • Certified Manufacturing: Good Manufacturing Practice (GMP) compliance is mandatory for suppliers aiming for global markets.
  • Quality Attributes: API must meet specifications for purity (>98%), residual solvents, microbial limits, and endotoxin levels under USP, BP, or Ph. Eur standards.

Key Supplier Criteria for Foscarnet Sodium API

  • GMP Certification: Ensures traceability and quality.
  • Batch Consistency: Critical for dosage accuracy.
  • Supply Stability: Ability to deliver on time, especially during high demand.
  • Price competitiveness: Competitive pricing applies, considering raw material and production costs.
  • Regulatory Documentation: Certificates of Analysis (CoA), Material Safety Data Sheets (MSDS), and registration dossiers.

Contract Manufacturing and Sourcing Strategies

  • Vertical Integration: Companies may partner directly with API producers or engage contract manufacturing organizations (CMOs).
  • Geographical Diversification: Reduces dependency on single-source suppliers.
  • Long-term Supply Agreements: Secure priority access and pricing stability.

Trends and Outlook

  • Increased Chinese and Indian API production capacity due to lower manufacturing costs.
  • Stringent quality demands leading to higher compliance standards.
  • Potential for shortages amid geopolitical tensions and supply chain disruptions.

Regulatory and Procurement Considerations

  • Verification through supplier audits and dossier review.
  • Import/export restrictions may impact procurement.
  • Use of authorized distributors or verified sourcing platforms enhances compliance.

Summary Table

Aspect Details
Major producing countries China, India, US
Key suppliers Zhejiang Jiuzhou, Cipla, Sun Pharma
Quality standards GMP compliant, USP/BP/Ph Eur specs
Regulatory hurdles Certification, documentation needed
Supply risks Geopolitical, pandemic disruptions

Key Takeaways

  • The bulk API for foscarnet sodium predominantly originates from China and India, with regulatory standards requiring GMP compliance.
  • Suppliers in these countries control the majority of the global supply, with increasing focus on quality and regulatory compliance.
  • Supply chain diversification and long-term contracts are recommended to mitigate shortages.
  • Regulatory compliance, including comprehensive documentation, remains critical in sourcing decisions.
  • The high reliance on Chinese and Indian API producers drives cost but presents geopolitical and supply risks.

FAQs

1. Who are the largest API manufacturers for foscarnet sodium?
Zhejiang Jiuzhou Pharmaceutical (China), Cipla, and Sun Pharmaceutical Industries (India).

2. What quality standards must APIs for foscarnet sodium meet?
API must meet GMP standards and specifications outlined by USP, BP, or Ph. Eur., with purity over 98%.

3. How does the source country influence API quality?
Chinese and Indian API producers typically adhere to GMP, but quality can vary; due diligence and audits are necessary.

4. Are there regional restrictions on importing foscarnet sodium API?
Import restrictions vary; US, EU, and other markets require compliance with local regulations, including certifications.

5. How can supply chain risks for API sourcing be mitigated?
Diversify suppliers across regions, establish long-term contracts, and verify supplier compliance and quality certifications.


References

[1] U.S. Pharmacopeia Convention. (2022). USP Monograph for Foscarnet Sodium.
[2] European Pharmacopoeia. (2022). Monograph for Foscarnet Sodium.
[3] MarketWatch. (2022). Global API Manufacturing Output and Trends.
[4] IQVIA. (2021). API Market Report: Chinese and Indian Production Overview.
[5] World Health Organization. (2020). Good Manufacturing Practices for Active Pharmaceutical Ingredients.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.